Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8079683 | 0.86 | TSHR (0.32) | — | |
| SCHEMBL3727014 | 0.79 | MEN1 (0.48) | MEN1KMT2APOLBGAACYP2C9 | |
| SCHEMBL21981138 | 0.78 | MEN1 (0.35) | MEN1KMT2APOLBGAACYP2C9 | |
| SCHEMBL2322350 | 0.78 | TSHR (0.43) | MEN1KMT2AGAA | |
| SCHEMBL22733778 | 0.72 | LPAR3 (0.48) | MEN1KMT2APOLB | |
| SCHEMBL5961193 | 0.67 | CYP3A4 (0.48) | MEN1KMT2APOLBGAACYP2C9 | |
| SCHEMBL16660508 | 0.67 | CYP3A4 (0.39) | MEN1KMT2APOLB | |
| SCHEMBL16482959 | 0.66 | KMT2A (0.39) | MEN1KMT2APOLBGAACYP2C9 | |
| SCHEMBL4564740 | 0.64 | — | — | |
| SCHEMBL21409643 | 0.64 | LPAR3 (0.48) | MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038588-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF STATUS EPILEPTICUS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-02-05 | — | — | US | claimed |
| US-20090176802-A1 | ANTIDOTES TO EXOGENOUS NEUROTOXIC AGENTS | PAPADOPOULOS VASSILIOS | 2009-07-09 | — | — | US | claimed |
| WO-2007092458-A1 | ANTIDOTES TO EXOGENOUS NEUROTOXIC AGENTS | SAMARITAN PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | claimed |
| US-12559784-B2 | In chemico test for toxicity | LEBRUN LABS LLC (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250369032-A1 | IN CHEMICO TEST FOR TOXICITY | LEBRUN LABS LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250101489-A1 | IN CHEMICO TEST FOR TOXICITY | LEBRUN LABS LLC | 2025-03-27 | — | — | US | disclosed |
| WO-2019180653-A1 | COMPOSITIONS, MATERIALS, AND METHODS FOR DEACTIVATING TOXIC AGENTS | INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE (INSTEM) (IN) | 2019-09-26 | — | — | WO | disclosed |
| US-9024106-B2 | Degradation of phosphate esters by high oxidation state molybdenum complexes | LEWIS & CLARK COLLEGE (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150038588-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF STATUS EPILEPTICUS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-02-05 | — | — | US | disclosed |
| US-20140357928-A1 | DEGRADATION OF PHOSPHATE ESTERS BY HIGH OXIDATION STATE MOLYBDENUM COMPLEXES | LEWIS & CLARK COLLEGE (US) | 2014-12-04 | — | — | US | disclosed |
| EP-2563121-A1 | METHODS AND COMPOSITIONS FOR PROTECTING AGAINST NEUROTOXIC AGENTS | Revalesio Corporation (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120121656-A1 | METHODS AND COMPOSITIONS FOR PROTECTING AGAINST NEUROTOXICITY OF A NEUROTOXIC AGENT, AND IMPROVING MOTOR COORDINATION ASSOCIATED WITH A NEURODEGENERATIVE CONDITION OR DISEASE | REVALESIO CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011137317-A1 | METHODS AND COMPOSITIONS FOR PROTECTING AGAINST NEUROTOXIC AGENTS | REVALESIO CORPORATION (US) | 2011-11-03 | — | — | WO | disclosed |
| US-7868220-B2 | Degradation of phosphate esters by molybdocene and tungstocene derivatives | LEWIS & CLARK COLLEGE (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100137672-A1 | DEGRADATION OF PHOSPHATE ESTERS BY MOLYBDOCENE AND TUNGSTOCENE DERIVATIVES | LEWIS & CLARK COLLEGE (US) | 2010-06-03 | — | — | US | disclosed |
| US-20090176802-A1 | ANTIDOTES TO EXOGENOUS NEUROTOXIC AGENTS | PAPADOPOULOS VASSILIOS | 2009-07-09 | — | — | US | disclosed |
| US-20080056933-A1 | Automated, ultraviolet, radiofrequency, electrostatic sterilization; hepa filters; chemical, biotoxin decontamination; environmental sampling device, sensor, control system, audio output, data transmitter, global positioning satellite receiver, radio identification tag, vacuum, floor washer, waterproof | SOVEREIGN DEED, LLC | 2008-03-06 | — | — | US | disclosed |
| WO-2007092458-A1 | ANTIDOTES TO EXOGENOUS NEUROTOXIC AGENTS | SAMARITAN PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176802-A1 | ANTIDOTES TO EXOGENOUS NEUROTOXIC AGENTS | INA, ACHE, NLN | MEN1 2598/4885KMT2A 4026/4885POLB 2564/4885 |
| US-20150038588-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF STATUS EPILEPTICUS | CHRNA3, GAP43, CHRNA5 | MEN1 3486/4885KMT2A 841/4885POLB 3268/4885 |
| US-12559784-B2 | In chemico test for toxicity | ALPP, ALPI, CUTA | MEN1 2759/4885KMT2A 3500/4885POLB 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.